新学期临近，对于许多杭州的初二女生和家长来说，这个寒假除了走亲访友、体育锻炼、参与实践 等，还多了一件关乎健康的"大事"——接种国家免疫规划提供的免费双价HPV疫苗。 "很多家长关心为什么要这么早给孩子接种？"专家提到，研究显示，我国女性HPV感染的第一个高 峰为17—24岁，且近年来宫颈癌发病日益年轻化，最小发病年龄已低至15岁。因此在感染高峰到来前接 种疫苗建立保护屏障至关重要，"9—14岁女孩仅需接种两剂次，就能达到很好的保护效果，实现'早接 种、早保护'。" 记者了解到，除了国家免疫规划提供的免费双价HPV疫苗外，适龄女生也可自愿、自费选择其他不 同品牌、不同价型的HPV疫苗进行替代接种。 对于想要选择九价疫苗的家长和孩子来说，眼下也是一个不错的窗口期。目前，上城区、拱墅区、 西湖区、萧山区、余杭区、富阳区、桐庐县、建德市、淳安县等地正在开展HPV疫苗接种惠民活动，9- 14岁女生全程接种两剂次（按0、6月接种）进口九价HPV疫苗可享"减免1剂次疫苗费用"；预计临安区 和钱塘区将于3月1日开始。家长可选择居住地或学校所在的社区卫生服务中心预防接种门诊进行接种， 建议提前通过浙里办App上的"浙里接种" ...

（来源：廊坊日报） 转自：廊坊日报 本报讯（记者 郑爽 通讯员 任蕊）日前，家住安次区豪邸坊小区的居民刘女士，带着刚满13岁的女儿免 费接种HPV疫苗，"孩子一放寒假就带她来打了，整个过程高效方便。" 为保障儿童青少年健康成长，根据国家疾控局等七部门印发的《关于将人乳头瘤病毒疫苗纳入国家免疫 规划有关工作事宜的通知》要求，自2025年11月10日起，全国范围内为2011年11月10日以后出生的满13 周岁女孩，免费接种2剂次双价HPV疫苗。 世界卫生组织（WHO）推荐，9~14岁女孩是HPV疫苗接种的首要人群。HPV主要通过性行为感染，在 感染风险显著增加之前（即发生性行为年龄之前）接种，能获得最佳的保护效果，实现"早接种，早保 护"。同时大量数据表明，这个年龄段接种能够获得最佳的预防效果，是最及时、最经济、最有效的保 护措施。基于充分的科学论证和国际经验，我国确定了该防护策略。 接种对象：2011年11月10日以后出生年满13周岁的女孩。 接种程序：接种2剂次双价HPV疫苗，间隔6个月。已完成其他HPV疫苗（包括双价、四价或九价）全程 接种的孩子无需重复接种。 工作人员表示，我市除免疫规划双价HPV疫苗免费 ...

Core Viewpoint - Watson Bio's HPV vaccine is expected to benefit significantly from the inclusion of the bivalent HPV vaccine in the national immunization program starting November 2025, with Yunnan province already implementing a free vaccination policy, indicating substantial growth potential for the company's HPV vaccine sales [1] Group 1: Production Capacity and Expansion Plans - The company is currently assessing whether its HPV vaccine production capacity can meet the market demand set by the national immunization program and is considering expansion plans [1] - The company emphasizes that the final procurement results will depend on negotiations with provincial disease control centers, and further contracts will need to be signed for production and supply [1] Group 2: Clinical Progress and Market Strategy - Watson Bio's nine-valent HPV vaccine is currently in Phase III clinical trials, and any significant progress in the development of its vaccines will be disclosed in a timely manner [1] - The company aims to leverage the supportive policies in Yunnan's biopharmaceutical sector to accelerate the market entry of its high-priced HPV vaccine [1] Group 3: Sales Growth Targets - The company has not disclosed specific sales growth targets for its HPV vaccine for 2026, indicating that further information will be provided as it becomes available [1]

Core Viewpoint - Watson Bio (300142.SZ) has officially launched 8 self-developed vaccine products (14 specifications) for sale, indicating a strong position in the vaccine market [1] Group 1: Product Offerings - The company has launched the following vaccines: - 13-valent pneumococcal conjugate vaccine (both vial and pre-filled syringe types) - Bivalent HPV vaccine (both vial and pre-filled syringe types) - 23-valent pneumococcal polysaccharide vaccine (both vial and pre-filled syringe types) - Haemophilus influenzae type b conjugate vaccine (both vial and pre-filled syringe types) - Group A and C meningococcal polysaccharide conjugate vaccine (both vial and pre-filled syringe types) - ACYW135 group meningococcal polysaccharide vaccine (both vial and pre-filled syringe types) - Group A and C meningococcal polysaccharide vaccine (vial type) - Adsorbed acellular DTP combined vaccine (vial type) [1] Group 2: Market Position - The company does not currently offer any influenza vaccines among its listed products, which may indicate a focused strategy on other vaccine types [1]

Group 1 - The State Administration for Market Regulation is conducting an investigation and assessment of the competitive status of the food delivery platform market in accordance with the Anti-Monopoly Law of the People's Republic of China [1] - The National Healthcare Security Administration, in conjunction with the Ministry of Finance, announced the nationwide implementation of cross-provincial pooling of personal accounts for basic medical insurance, allowing near relatives to use these accounts for medical treatment and medication [2] - The Ministry of Finance and the State Taxation Administration announced the cancellation of the value-added tax export rebate for photovoltaic products starting from April 1, 2026 [2] Group 2 - The China Securities Regulatory Commission has increased the whistleblower reward, with a maximum reward of 1 million yuan, significantly raising the reward standard from 1% to 3% of the penalty amount for securities and futures violations [6] - The CSRC has initiated an investigation into Tianpu Rubber Technology Co., Ltd. for significant omissions in its announcement regarding abnormal stock price fluctuations [9]

Group 1 - The Beijing CDC has launched a program for free HPV vaccination for girls aged 13 and above, specifically targeting those born after November 10, 2011 [1] - Eligible girls can receive two doses of the bivalent HPV vaccine, with a recommended interval of 6 months between doses, and should complete the vaccination before turning 18 [1] - Vaccination can be arranged through schools or by using various online platforms and services provided by the Beijing CDC [1] Group 2 - Starting from November 10, 2025, the HPV vaccine will be included in the national immunization program, with a focus on new first-year junior high school girls entering school in September 2025 [2] - The Beijing CDC clarified that girls who have received the first dose of the HPV vaccine under the local initiative can continue with the same vaccine to complete their vaccination [2] - Girls who have not received the local initiative vaccine but meet the national immunization criteria can opt for the HPV vaccine under the national program [2]

Core Viewpoint - Watson Bio has launched a total of 8 self-developed vaccine products (14 specifications) for sale, focusing on preventing diseases caused by specific pathogens [1] Group 1: Vaccine Products - The company offers the following vaccines: 13-valent pneumonia conjugate vaccine (both vial and pre-filled types), bivalent HPV vaccine (both vial and pre-filled types), 23-valent pneumonia polysaccharide vaccine (both vial and pre-filled types), type b Haemophilus influenzae conjugate vaccine (both vial and pre-filled types), A and C group meningococcal polysaccharide conjugate vaccine (both vial and pre-filled types), ACYW135 group meningococcal polysaccharide vaccine (both vial and pre-filled types), A and C group meningococcal polysaccharide vaccine (vial type), and adsorbed acellular DTP combined vaccine (vial type) [1] Group 2: Marketing and Strategy - The company aims to strengthen product marketing efforts by developing practical strategies and execution measures, enhancing talent development, and leveraging scientific outreach to boost confidence and implementation [1] - The focus will be on improving the coverage and penetration rates of terminal channels to create value for the company and its shareholders [1]

Core Viewpoint - The Chinese government has announced the inclusion of the HPV vaccine in the national immunization program, aiming to reduce the burden of cervical cancer and promote public health [3] Group 1: Policy Announcement - The National Health Commission, along with six other departments, issued a notification regarding the inclusion of the HPV vaccine in the national immunization program [3] - Starting from November 10, 2025, girls born after November 10, 2011, who are at least 13 years old will receive two doses of the bivalent HPV vaccine for free [3] Group 2: Health Impact - This initiative is a significant step towards reducing the family burden associated with cervical cancer and other diseases caused by HPV [3] - The program reflects a national commitment to advancing public health and reducing disease incidence [3]

Group 1: Policy and Industry Dynamics - The Shanghai Stock Exchange released guidelines to expand the fifth listing standard for commercial rocket companies on the Sci-Tech Innovation Board, aiming to support the innovation and development of the commercial aerospace sector [1][17] - The guidelines consist of 14 articles detailing requirements related to business scope, "hard technology" attributes, and standards for commercial rocket enterprises, providing targeted support for high-quality companies without significant revenue [1][17] - Several rocket companies have recently submitted IPO counseling records, indicating a growing interest in capital market participation [1][17] Group 2: Market Overview and Trends - The commercial rocket industry is at a critical stage of large-scale commercialization, necessitating further support from the capital market [2][18] - The Sci-Tech Innovation Board focuses on hard technology, including sectors like electronic chips, emerging software, and new information technology services, reflecting the rise of advanced manufacturing in China [2][18] - Recent trends show a rebound in the Sci-Tech Innovation Board, particularly in sectors such as chips, information technology, and new materials [3][19] Group 3: Sector Performance - The top five industries on the Sci-Tech Innovation Board are electronics, biomedicine, power equipment, computers, and machinery, collectively accounting for 88.2% of the board's market capitalization [4][20] - The semiconductor sector has seen significant interest, with a notable rebound in chip stocks driven by demand for AI computing infrastructure [21] - The high-end equipment manufacturing sector is experiencing growth, with a 15.4% year-on-year increase in engineering machinery import and export trade, reflecting a recovery in overseas demand [22] Group 4: Investment Opportunities - The AI computing demand is expected to surge, with continued capital investment from cloud vendors driving high demand for advanced chips [21] - The domestic engineering machinery update cycle is starting, supported by favorable policies in real estate and infrastructure [22] - The pharmaceutical sector remains active, with multiple innovative drugs and medical devices receiving approvals, indicating a robust pipeline for growth [23]

Core Viewpoint - Watson Bio, once valued at over 100 billion, is struggling under dual pressures of governance disorder and declining performance, highlighted by regulatory actions for failing to follow proper salary review procedures for executives in 2023 and 2024 [1][7]. Group 1: Governance Structure and Oversight Deficiencies - The company has repeatedly failed to adhere to basic corporate governance principles, specifically regarding the approval of executive salaries, as mandated by the Corporate Governance Guidelines [2][8]. - This oversight reflects a lack of internal governance structure and effective supervisory mechanisms, potentially due to management's disregard for rules or ineffective internal checks and balances [2][8]. - Regulatory bodies have noted multiple violations of listing rules, and the company has a history of governance issues since its IPO in 2010, including flaws in decision-making processes [2][8]. Group 2: Performance Decline and Internal Control Issues - Watson Bio's financial performance has deteriorated significantly, with a reported 31.41% year-on-year decline in revenue and a 66.1% drop in net profit for 2024 [3][9]. - Contributing factors to this decline include intensified domestic market competition, significant price reductions for its core product, the bivalent HPV vaccine, and decreased willingness for self-paid vaccinations [3][9]. - For the first three quarters of 2025, the company reported revenues of 1.719 billion, a 19.73% decrease year-on-year, and a net profit of 163 million, down 36.24% [10]. Group 3: Founder Cashing Out and Governance Conflicts - Amidst internal control and performance pressures, the founder, Li Yunchun, has been consistently cashing out since 2016, totaling approximately 4 billion [4][11]. - Li Yunchun's direct shareholding has plummeted to 1.7%, with other founders also seeing significant reductions in their holdings, leading to a lack of effective governance due to a dispersed ownership structure [5][11]. - Since 2011, Watson Bio executives have engaged in 97 stock transactions, with 78 being sell-offs, totaling 124 million shares, raising concerns about governance and investor trust [12].